{"result": "(\"entity\"<|>GERBER P. FORMULAS<|>ORGANIZATION<|>Gerber P. Formulas is a brand known for its nutritional products, particularly those containing live probiotic bacteria.)\n##\n(\"entity\"<|>AM J CLIN NUTR<|>ORGANIZATION<|>The American Journal of Clinical Nutrition is a peer-reviewed journal that publishes research on clinical nutrition and related fields.)\n##\n(\"entity\"<|>PHILIPSEN-GEERLING BJ<|>PERSON<|>Philipsen-Geerling BJ is a researcher who has contributed to studies on nutrition in Crohn's disease.)\n##\n(\"entity\"<|>BRUMMER RJM<|>PERSON<|>Brummer RJM is a researcher involved in clinical nutrition and metabolism care.)\n##\n(\"entity\"<|>PEARSON M<|>PERSON<|>Pearson M is a researcher who has studied food intolerance and its relation to Crohn's disease.)\n##\n(\"entity\"<|>TEAHON K<|>PERSON<|>Teahon K is a researcher who has contributed to studies on food intolerance and Crohn's disease.)\n##\n(\"entity\"<|>LEVI AJ<|>PERSON<|>Levi AJ is a researcher who has worked on understanding food intolerance in relation to Crohn's disease.)\n##\n(\"entity\"<|>BJARNASON I<|>PERSON<|>Bjarnason I is a researcher who has studied food intolerance and its effects on Crohn's disease.)\n##\n(\"entity\"<|>E. CABRÉ GELADA<|>PERSON<|>E. Cabré Gelada is a researcher focused on nutrition and inflammatory bowel disease.)\n##\n(\"entity\"<|>COMPLEJO HOSPITALARIO UNIVERSITARIO ALBACETE<|>ORGANIZATION<|>The Complejo Hospitalario Universitario Albacete is a healthcare institution involved in endocrinology and nutrition.)\n##\n(\"entity\"<|>EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM<|>ORGANIZATION<|>ESPEN is a scientific society that focuses on clinical nutrition and metabolism, providing guidelines and definitions related to nutritional support.)\n##\n(\"entity\"<|>NUTRICIÓN CLÍNICA Y METABOLISMO<|>EVENT<|>Nutrition Clinical and Metabolism is a field of study and practice that focuses on the nutritional needs and metabolic processes in patients.)\n##\n(\"relationship\"<|>GERBER P. FORMULAS<|>AM J CLIN NUTR<|>Gerber P. Formulas is referenced in the American Journal of Clinical Nutrition for its probiotic products<|>7)\n##\n(\"relationship\"<|>PHILIPSEN-GEERLING BJ<|>BRUMMER RJM<|>Philipsen-Geerling BJ and Brummer RJM collaborated on research regarding nutrition in Crohn's disease<|>6)\n##\n(\"relationship\"<|>PEARSON M<|>TEAHON K<|>Pearson M and Teahon K worked together on studies related to food intolerance and Crohn's disease<|>6)\n##\n(\"relationship\"<|>LEVI AJ<|>BJARNASON I<|>Levi AJ and Bjarnason I are researchers who have contributed to the understanding of food intolerance in Crohn's disease<|>6)\n##\n(\"relationship\"<|>E. CABRÉ GELADA<|>NUTRICIÓN CLÍNICA Y METABOLISMO<|>E. Cabré Gelada's work focuses on nutrition in inflammatory bowel disease, which is part of the field of clinical nutrition and metabolism<|>8)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM<|>COMPLEJO HOSPITALARIO UNIVERSITARIO ALBACETE<|>The Complejo Hospitalario Universitario Albacete follows guidelines set by ESPEN for clinical nutrition practices<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Gerber P. Formulas containing live probiotic bacteria .Am J Clin Nutr. 2004 Sep; 80(3):783; 783-4.\n\n52. Philipsen-Geerling BJ, Brummer RJM. Nutrition in Crohn's disease. Clin Nutr Metab Care 2000; 3:305-309.\n\n53. Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn's disease. Gut 1993; 34:783-87.\n\n54. E. Cabré Gelada. Nutrición y enfermedad inflamatoria intestinal. Nutr Hosp 2007; 22 (Supl. 2):65-73.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# Tema 31.\n## Soporte nutricional en pacientes con fallo intestinal\n\nJosé Joaquín Alfaro Martínez\nElena Carrillo Lozano\nAntonio Hernández López\nFrancisco Botella Romero\nServicio de Endocrinología y Nutrición. Complejo Hospitalario Universitario. Albacete\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 497-510.\n\n1. Introducción\n2. Fisiopatología\n3. Diagnóstico\n4. Objetivos nutricionales\n5. Valoración nutricional\n6. Dietética\n7. Soporte nutricional artificial\n8. Resumen\n9. Bibliografía\n\n### 1. Introducción\n\nEl fallo intestinal fue descrito por primera vez en 1981 por Fleming y Remington como la «reducción de la masa intestinal que da como resultado una pérdida de capacidad de digestión y absorción de nutrientes»¹. Esta definición fue cambiando a lo largo del tiempo¹ y se completó incluyendo la necesidad de suplementación nutricional para mantener la salud y/o el crecimiento².\n\nLa European Society for Clinical Nutrition and Metabolism (ESPEN) ha sido la primera sociedad científica que ha propuesto una definición formal de fallo intestinal¹: se define fallo intestinal como la reducción de la función intestinal por debajo del mínimo necesario para la absorción de macronutrientes y/o agua y electrolitos, de forma que es necesaria la suplementación intravenosa para mantener la salud y el crecimiento³. Es decir, en la definición de la ESPEN se incluye la necesidad de nutrición parenteral (NP), o al menos hidratación parenteral, para diagnosticar fallo intestinal, dejando el término de insuficiencia intestinal reservado a aquellas situaciones en que es posible mantener la salud y el crecimiento solo con soporte nutricional oral o enteral.\n\nSegún la ESPEN, el término insuficiencia intestinal puede ser considerado en las siguientes situaciones¹:\n\n- Ingesta reducida de comida con función intestinal normal.\n- Función intestinal alterada pero absorción conservada.\n- Enfermedad inflamatoria intestinal tratada con nutrición enteral.\n- Pacientes tratados con NP porque rechazan nutrición enteral, la cual podría ser efectiva.\n- Pacientes con función intestinal reducida, con alteración de la absorción, pero en los cuales la salud y el crecimiento se mantienen mediante la suplementación oral, nutrición enteral, enteroclisis de alimentación o aquellos que solo necesitan suplementos de vitaminas y elementos traza.\n\nLa definición de fallo intestinal de la ESPEN incluye una clasificación funcional y otra fisiopatológica tanto para el fallo intestinal agudo como crónico, y además\n---\nBLOQUE: NUTRICIÓN EN PATOLOGÍA DEL TUBO DIGESTIVO\n\nuna clasificación clínica para el fallo intestinal crónico (tabla 1). Desde el punto de vista funcional, se clasifica el fallo intestinal como3:\n\n- Tipo I: agudo, de corta duración y con frecuencia autolimitado.\n- Tipo II: supone la prolongación de una situación aguda, a menudo en un paciente metabólicamente inestable que requiere suplementación intravenosa durante semanas o meses.\n- Tipo III: trastorno crónico, en pacientes metabólicamente estables, que requiere suplementación intravenosa durante meses o años, y que puede ser reversible o irreversible.\n\nEl fallo intestinal de tipo I y II puede considerarse una situación aguda, en la que es esperable que el paciente logre la autonomía intestinal. Esta situación suele encontrarse en las plantas quirúrgicas, como resultado de intervenciones urgentes o de complicaciones de la cirugía. Concretamente, el fallo intestinal tipo II suele ocurrir tras catástrofes abdominales, como isquemia intestinal, vólvulos o traumatismos que requieren resecciones intestinales extensas o bien tras complicaciones de la cirugía tales como dehiscencia de suturas o daños inadvertidos en el intestino, que condicionan la aparición de una fístula o la neces\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}